Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-134-VI | Cabozantinib | VEGFR2/MET | RTK | 10.9194 | 0.6362 | -0.0167 | -0.0063 | 5.0000 | 12.725 | 0.88168 |
| HCC1806 | ABT-737 | Bcl2/XL | Misc | 12.0843 | 0.7293 | -0.0285 | 0.0138 | 5.0000 | 12.4641 | 0.7932 |
| HCC70 | Dinaciclib | pan CDK | Cell cycle | 0.01286 | -0.9093 | 0.8338 | 0.3254 | 5.0000 | 0.015807 | 0.9991 |
| HCC1419 | Dinaciclib | pan CDK | Cell cycle | 0.026695 | -0.4761 | 0.5131 | 0.1238 | 5.0000 | 0.030191 | 0.99589 |
| HCC38 | Luminespib | HSP90 | Misc | 0.0071367 | -0.2087 | 0.6295 | 0.1926 | 5.0000 | 0.0076296 | 0.99771 |
| HCC1806 | Volasertib | PLK | Cell cycle | 0.0027998 | -0.1323 | 0.7262 | 0.2950 | 5.0000 | 0.0029495 | 0.99776 |
| T47D | Dinaciclib | pan CDK | Cell cycle | 0.019853 | -0.2109 | 0.4815 | 0.0484 | 5.0000 | 0.021113 | 0.99494 |
| MDA-MB-134-VI | Volasertib | PLK | Cell cycle | 0.0027209 | -0.6274 | 1.0260 | 0.2671 | 5.0000 | 0.0032225 | 0.99553 |
| HCC70 | Luminespib | HSP90 | Misc | 0.007646 | -0.5826 | 0.7792 | 0.2409 | 5.0000 | 0.0088695 | 0.99752 |
| SK-BR-3 | Dasatinib | BCR/ABL | MAPK/nRTK | 3.6452 | 0.0810 | 0.0617 | 0.0233 | 5.0000 | 3.5272 | 0.98252 |
| SK-BR-3 | Cabozantinib | VEGFR2/MET | RTK | 9.7073 | 0.4422 | 0.0013 | 0.0011 | 5.0000 | 12.0523 | 0.95604 |
| HCC1500 | Volasertib | PLK | Cell cycle | 0.011592 | 0.2861 | 0.3454 | 0.0484 | 5.0000 | 0.0099361 | 0.97732 |
| CAL-85-1 | Everolimus | mTOR1 | PI3K/mTOR | 0.0015471 | 0.3707 | 0.5762 | 0.0915 | 5.0000 | 0.0011149 | 0.86907 |
| PDX1258 | Luminespib | HSP90 | Misc | 0.01007 | -0.2899 | 0.6101 | 0.1943 | 5.0000 | 0.011049 | 0.99799 |
| MDA-MB-361 | Dinaciclib | pan CDK | Cell cycle | 0.011817 | -0.2748 | 0.6004 | 0.0836 | 5.0000 | 0.013067 | 0.99187 |
| HCC1143 | Dinaciclib | pan CDK | Cell cycle | 0.015148 | -0.2527 | 0.5451 | 0.1106 | 5.0000 | 0.016398 | 0.9989 |
| MDA-MB-134-VI | PF-4708671 | p70S6K | PI3K/mTOR | 11.8417 | 0.7092 | -0.0287 | -0.0026 | 5.0000 | 12.2595 | 0.80506 |
| HCC1395 | A-1210477 | Mcl-1 | Misc | 14.7951 | 0.8591 | 0.0009 | 0.0010 | 5.0000 | 13.8656 | 0.73508 |
| SK-BR-3 | Saracatinib | SRC | MAPK/nRTK | 4.9166 | 0.2786 | 0.0221 | 0.0102 | 5.0000 | 4.2128 | 0.96696 |
| HCC70 | Ceritinib | ALK | RTK | 3.1923 | -0.8808 | 0.1379 | 0.0703 | 5.0000 | 3.9213 | 0.99483 |
| HCC1428 | TGX221 | PI3Kb | PI3K/mTOR | Inf | 0.7695 | 0.0143 | 0.0033 | 4.9999 | 3.7973 | 0.75865 |
| MCF 10A | Cabozantinib | VEGFR2/MET | RTK | 25.9104 | 0.8434 | -0.0114 | 0.0040 | 4.9998 | 11.7694 | 0.81226 |
| MDA-MB-453 | PF-4708671 | p70S6K | PI3K/mTOR | 4.291 | 0.0482 | 0.0418 | 0.0294 | 4.9998 | 4.2285 | 0.98022 |
| HCC1806 | Cediranib | VEGFR/cKIT | RTK | 4.9315 | 0.0954 | 0.0645 | 0.0363 | 4.9998 | 4.7786 | 0.98723 |
| PDX1258 | Trametinib | MEK | MAPK/nRTK | Inf | 0.8500 | 0.0424 | 0.0050 | 4.9997 | 0.028253 | 0.88698 |